Blues TEC Issues Negative Review Of Cyberonics’ VNS Therapy For Depression
This article was originally published in The Gray Sheet
Executive Summary
The BlueCross BlueShield Association's Technology Evaluation Center (TEC) says there is insufficient evidence to conclude that Cyberonics' VNS Therapy improves net health outcomes of patients with treatment-resistant depression
You may also be interested in...
Cyberonics Seeks Coverage For Anti-Depression Implant In Select Patients
Cyberonics is pursuing national coverage of its VNS Therapy implant for treatment-resistant depression in a select group of patients, despite continued payor skepticism as to the technology's effectiveness
Cyberonics Seeks Coverage For Anti-Depression Implant In Select Patients
Cyberonics is pursuing national coverage of its VNS Therapy implant for treatment-resistant depression in a select group of patients, despite continued payor skepticism as to the technology's effectiveness
Cyberonics Nabs Approval For Depression Device, Plans For Reimbursement
Cyberonics predicts reimbursement for VNS Therapy for treatment-resistant depression (TRD) will be fully secured by 2007, despite encountering protracted difficulties in gaining FDA approval